Zhongsheng Pharma's Anlotinib Tablets included in national medical insurance catalog

Guangdong Zhongsheng Pharmaceutical Co. announced on December 7, 2025, that its innovative Class 1 drug, Anlotinib Tablets (brand name: Anruiwei), has been successfully included in the National Medical Insurance Drug Catalog (2025). This follows negotiations with the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, and applies to basic medical insurance, maternity insurance, and work-related injury insurance.

Anlotinib Tablets are the world's first innovative drug targeting the influenza A virus RNA polymerase PB2 subunit, approved by the National Medical Products Administration in May 2025. Designed for adult patients with uncomplicated influenza A, it offers rapid, potent, and low-resistance properties. The drug's inclusion in Category B of the National Medical Insurance Drug Catalog is expected to benefit more patients by providing an economical, safe, and accessible treatment option.

The company anticipates this inclusion will positively impact its market promotion and future sales, contributing to its long-term operational development. Zhongsheng Pharma also noted that other core products, including Leritide Tablets and Compound Xueshuantong Capsules, remain in the updated catalog. The company cautions investors that future sales may be influenced by industry policy changes and market conditions, though no significant short-term impact on performance is expected.